GlassScriptPhysician profile
Sunita Tummala
NPI 1568537207
$377,617.33
in general payments reported to CMS, 2019-2025
68 companies · $84K in 2025
The $84K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $29K · 2021: $68K · 2022: $84K · 2023: $28K · 2024: $35K · 2025: $84K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $126K · Food and Beverage: $9,957 · Travel and Lodging: $7,285 · Consulting Fee: $3,325 · Education: $90.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125,520.00 |
| Food and Beverage | $9,957.34 |
| Travel and Lodging | $7,284.58 |
| Consulting Fee | $3,325.00 |
| Education | $90.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $159,890.90 | 2020-2025 | Qulipta, Ubrelvy, Botox |
| Biogen, INC. | $93,371.03 | 2019-2025 | Tysabri, Vumerity, Spinraza |
| Alexion Pharmaceuticals, INC. | $83,830.98 | 2019-2025 | Ultomiris, Soliris |
| Pfizer INC. | $18,966.89 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $7,843.54 | 2022 | |
| Emd Serono, INC. | $2,836.81 | 2019-2025 | Mavenclad |
| Allergan, INC. | $1,217.96 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $1,041.46 | 2019-2025 | |
| Ucb, INC. | $823.53 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Supernus Pharmaceuticals, INC. | $501.11 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $424.30 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Genentech USA, INC. | $395.41 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Genzyme Corporation | $359.17 | 2019-2023 | |
| Neurelis, INC. | $352.94 | 2020-2025 | Valtoco |
| Neurocrine Biosciences, INC. | $345.09 | 2019-2023 | Ongentys, Ingrezza |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunita Tummala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.